Ireland introduces fee for incomplete/incorrect applications
This article was originally published in SRA
The Irish Medicines Board has introduced an "invalidation fee" to deal with incomplete or incorrect applications submitted by companies under various categories1,2. Applicants can incur up to 10% of the fee for making invalid submissions.
You may also be interested in...
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.
Companies are being encouraged to become “early adopters” of the EU Clinical Trials Information System when it goes live in December 2021.
Drug companies will be able to “play around” with the new EU Clinical Trials Information System in a secure testing environment before it goes live in approximately 15 months.